Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

• Published in: Gynecologic oncology Vol. 168; pp. 157 - 165
• Main Authors: Harold, Justin, Bellone, Stefania, Manavella, Diego D., Mutlu, Levent, McNamara, Blair, Hartwich, Tobias Max Philipp, Zipponi, Margherita, Yang-Hartwich, Yang, Demirkiran, Cem, Verzosa, Miguel Skyler, Choi, Jungmin, Dong, Weilai, Buza, Natalia, Hui, Pei, Altwerger, Gary, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2023
• Subjects: Animals; Ataxia Telangiectasia Mutated Proteins - genetics; ATR inhibitors; ATRX; BAY1895344; DAXX; Female; Humans; Leiomyosarcoma - drug therapy; Leiomyosarcoma - genetics; Leiomyosarcoma - pathology; Mice; Mice, SCID; Mutation; Uterine leiomyosarcoma; Uterine Neoplasms - drug therapy; Uterine Neoplasms - genetics; Uterine Neoplasms - pathology; X-linked Nuclear Protein - genetics; X-linked Nuclear Protein - metabolism; Uterine leiomyosarcoma; BAY1895344; DAXX; ATR inhibitors; ATRX

Uterine leiomyosarcoma (uLMS) is a rare, highly aggressive malignancy. Recent data suggest 50% of uLMS may harbor alterations in the ATRX gene and such mutations may confer sensitivity to ataxia-telangiectasia-and-Rad3-related (ATR) kinase inhibitors. We sought to investigate the in vivo activity of...